- Net assets per share 6.24 pence at 31 March 2021 (2020: 2.50 pence). - Profit after tax of £3.09 million (2020: loss £0.30 million). - Investments at 31 March 2021 valued at £5.11 million (2020: £1.18 million). - Spend on new investments of £1.90 million (2020: £1.38 million).
- Investment realisation proceeds of £1.21 million (2020: £2.03 million). - Cash at 31 March 2021 of £0.05 million (2020: £0.90 million). - Post year end raised gross cash proceeds of £4.11 million under a placing and open offer in April 2021. - No part of the £3.00 million shareholder loan facility drawn down to date.
"Whilst the arrival of a number of Covid-19 vaccines and the associated roll-out of the global vaccination programs should now provide a pathway for the gradual easing of the social and economic restrictions currently in force, the full economic fallout from this pandemic remains uncertain. Against this economic backdrop, your Board will continue to maintain a rigorous and highly selective investment approach which is committed to delivering additional value for shareholders going forward. We remain confident in the underlying fundamentals, technologies and long-term potential for growth at the companies within our investment portfolio."